Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 17/20 | 0.42 |
| ▸ | CDC42BPB | Q9Y5S2 | 17/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 9/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673116 | 0.83 | JAK3 (0.50) | JAK3ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672948 | 0.77 | CDC42BPB (0.62) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672467 | 0.77 | CDC42BPB (0.62) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24673083 | 0.77 | ROCK1 (0.64) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24673150 | 0.76 | ROCK1 (0.53) | JAK3ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672151 | 0.74 | CDC42BPB (0.61) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24673059 | 0.72 | ROCK1 (0.62) | JAK3ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24673049 | 0.72 | EIF2AK4 (0.42) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672418 | 0.71 | ROCK1 (0.41) | ROCK1CDC42BPBROCK2CDC42BPANAMPT | |
| SCHEMBL20757701 | 0.70 | ROCK1 (0.40) | ROCK1CDC42BPBROCK2CDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | JAK3 669/4885ROCK1 1054/4885CDC42BPB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.